A2 Allele Polymorphism of the CYP17 Gene and Prostate Cancer Risk in an Iranian Population |
Karimpur-Zahmatkesh, Arezu
(Medical Genetics Department, Shahid Beheshti of Medical Science University)
Farzaneh, Farah (Department of Ob And Gyn, Shahid Beheshti of Medical Science University) Pouresmaeili, Farkhondeh (Medical Genetics Department, Shahid Beheshti of Medical Science University) Hosseini, Jalil (Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti of Medical Science University) Azarghashb, Eznollah (Social Medical Department, Shahid Beheshti of Medical Science University) Yaghoobi, Mohammad (Urology Department, Shahid Beheshti of Medical Science University) |
1 | Alberti C (2010). Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features. Eur Rev Med Pharmacol Sci, 14, 31-41. |
2 | Antognelli C, Mearini L, Talesa VN, et al (2005). Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. The Prostate, 63, 240-51. DOI ScienceOn |
3 | Barnes HJ, Arlotto MP, Waterman MR, et al (1991). Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proceedings of the National Academy of Sciences, 88, 5597. DOI ScienceOn |
4 | Bergman-Jungestrom M, Gentile M, Lundin AC, et al (1999). Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer, 84, 350-3. DOI |
5 | Camp NJ, Tavtigian SV (2002). Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Human Genetics, 71, 1475. DOI ScienceOn |
6 | Carey AH, Waterworth D, Patel K, et al (1994). Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Molecular Genetics, 3, 1873-6. DOI ScienceOn |
7 | Chen H, Griffin A, Wu Y, et al (2003). RNASEL mutations in hereditary prostate cancer. J Medical Genetics, 40, 21. DOI |
8 | Cicek MS, Conti DV, Curran A, et al (2003). Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. The Prostate, 59, 69-76. |
9 | Fan YS, Sasi R, Lee C, et al (1992). Localization of the human CYP17 gene (cytochrome P45017 [alpha]) to 10q24. 3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics, 14, 1110-1. DOI |
10 | Feigelson HS, Coetzee GA, Kolonel LN, et al (1997). A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57, 1063-5. |
11 | Gsur A, Bernhofer G, Hinteregger S, et al (2000). A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer, 87, 434-7. DOI |
12 | Gsur A, Feik E, Madersbacher S, et al. (2004). Genetic polymorphisms and prostate cancer risk. World J Urol, 21, 414-23. DOI |
13 | Habuchi T, Liqing Z, Suzuki T, et al (2000). Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res, 60, 5710-3. |
14 | Haiman CA, Hankinson SE, Spiegelman D, et al (1999). The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res, 59,1015-20. |
15 | Haiman CA, Stampfer MJ, Giovannucci E, et al (2001). The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiology Biomarkers &Prev, 10, 743-8. |
16 | Hong WK, Bast RC, Hait W, et al. (2010). Holland Frei cancer medicine eight, Pmph USA Ltd. |
17 | Lunn RM, Bell DA, Mohler JL, et al (1999). Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 20, 1727-31. DOI ScienceOn |
18 | Ntais C, Polycarpou A, Tsatsoulis A, et al (2003). Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol, 149, 469-77. DOI ScienceOn |
19 | Madigan MP, Gao YT, Deng J, et al (2003). CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population based study in China. Int J Cancer, 107, 271-5. DOI ScienceOn |
20 | Ntais C, Polycarpou A, Ioannidis JPA, et al (2003). Association of the CYP17 gene polymorphism with the risk of prostate cancer a meta-analysis. Cancer Epidemiol Biomarkers &Prev, 12, 120-6. |
21 | Picado-Leonard J, Miller Wl (1987). Cloning and Sequence of the Human Gene for P450cl7 (Steroid 17-Hydroxylase/17, 20 Lyase): Similarity with the Gene for P450c21. DNA, 6, 439-48. DOI ScienceOn |
22 | Sadjadi A, Nooraie M, Ghorbani A, et al. (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med, 10, 481-5. |
23 | Sarma AV, Dunn RL, Lange LA, et al (2008). Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF 1, and IGFBP 3 and prostate cancer risk in African American men: The Flint men's health study. The Prostate, 68, 296-305. DOI ScienceOn |
24 | Sobti R, Onsory K, Al-Badran AI, et al (2006). CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biology, 25, 287-94. DOI ScienceOn |
25 | Sobti RC, Gupta L, Thakur H, et al (2009). CYP17 gene polymorphism and its association in north Indian prostate cancer patients. Anticancer Res, 29, 1659-63. |
26 | Souiden Y, Mahdouani M, Chaieb K, et al (2010). CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population. Cancer Epidemiology, 35, 480-4. |
27 | Yang J, Wu H, Zhang W, et al (2006). Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front Biosci, 11, 2052-60. |
28 | Stanford JL, Noonan EA, Iwasaki L, et al (2002). A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiology Biomarkers Prev, 11, 243-7. |
29 | Yamada Y, Watanabe M, Murata M, et al (2001). Impact of genetic polymorphisms of 17-hydroxylase cytochrome P 450 (CYP17) and steroid 5 reductase type II (SRD5A2) genes on prostate cancer risk among the Japanese population. Int J Cancer, 92, 683-6. DOI |